Key clinical point: Biologic therapy may reduce the risk of PsA in patients with psoriasis.
Major finding: Treatment with biologics versus conventional DMARDs was associated with reduced risk of developing PsA (incidence risk ratio, 0.17).
Study details: A retrospective analysis of 1,626 with psoriasis treated with topical, therapy, biologic therapy, or conventional DMARDs at a single center.
Disclosures: Dr. Thaçi and Dr. Lo Giudice have no relevant financial disclosures.
FROM GRAPPA 2020 VIRTUAL ANNUAL MEETING